Keytruda Organ Failure Marketing & Claimant Acquisition

The litigation landscape

As of mid-2026 there is no Keytruda MDL, no bellwether schedule, no verdicts, and no settlements. The litigation is a collection of state court filings built on a failure-to-warn theory that is unusually well supported: checkpoint inhibitor immune-related adverse events are documented in the drug's own label, in the oncology literature, and in FDA pharmacovigilance data. Grade 3 and Grade 4 events, the ones that require hospitalization or leave permanent organ damage, occur in roughly 3 to 5 percent of treated patients depending on the indication and regimen. Given the volume of Keytruda administrations since 2014, the severe-event population runs into the tens of thousands nationally.

Merck generates more than $25 billion a year from Keytruda and will defend it accordingly, which is why firms without pharmaceutical litigation infrastructure typically enter through co-counsel or referral arrangements with firms that have tried immune-related drug injury cases before. For case acquisition the more important fact is timing. In pharmaceutical torts the pattern repeats: leads that cost a few hundred dollars before the MDL petition cost two to three times that once legal media and competitor spend arrive. Firms building Keytruda inventory now are buying at the front of that curve. MTAA's monthly Keytruda litigation update tracks docket movement, MDL petition activity, and current acquisition economics.

Who a campaign targets

• Strongest campaign targets: Patients treated with Keytruda who developed a Grade 3 or Grade 4 immune-related adverse event resulting in hospitalization, documented permanent organ damage, or death. Severe colitis, immune-mediated hepatitis, pneumonitis requiring steroid treatment, nephritis, and hypophysitis are the leading injury categories.
• Also in-scope: Caregivers and surviving family members of Keytruda patients, since a large share of this audience is reached through a spouse or adult child rather than the patient. Wrongful death claims are part of the pool.
• Key qualifying details to capture at intake: Confirmation of pembrolizumab treatment and the prescribing cancer center, the specific irAE diagnosis, hospitalization dates, whether the event was characterized as Grade 3 or 4 by the treating physician, and current organ function.
• Borderline / screening required: Grade 1 and Grade 2 events managed on an outpatient basis, events mentioned incidentally in follow-up notes without a severity grade, and cases where the cancer itself rather than the immune reaction caused the organ damage. These need records review before signing.

How MTAA runs Keytruda Organ Failure campaigns

Keytruda creative converts on specificity. The audience is cancer survivors and the people who cared for them, and they remember the event: the week in the hospital for colitis that would not stop, the liver numbers that sent oncology into a panic, the lung inflammation that meant steroids and oxygen. Ads that name those experiences outperform generic drug-injury copy by a wide margin, because the reader recognizes their own chart. Naming the drug and Merck in the creative helps, since patients know what they were infused with even when they cannot spell the generic name. Caregiver-directed creative, written to the spouse or adult child who managed the hospitalization, is a second track that should run from day one, and it is often the stronger performer on Facebook where this demographic indexes highest.

At current market conditions a well-structured Meta campaign should expect cost per lead in the $150 to $400 range and cost per signed case for qualified Grade 3 or 4 claimants in the $800 to $2,000 range, with the spread driven by creative quality and how tightly the lander qualifies on hospitalization and severity before the lead reaches intake. Those numbers hold because competition is still thin; they will not hold after an MDL petition. Campaigns run nationally, since Keytruda is administered at cancer centers in every state and there is no geographic concentration to work around. MTAA qualifies on the lander at keytrudaclaim.com, routes hospitalization-confirmed leads to the firm's intake, and reports at the cost-per-signed-case level, not cost per click.